Compass Pathways Reports Positive Outcomes From Second Phase 3 Trial Evaluating COMP360 Psilocybin For Treatment-Resistant Depression

Compass Pathways plc, a biotechnology company developing a psilocybin compound for treatment-resistant depression, reported positive outcomes from its second Phase 3 clinical trial. The trial evaluated two doses of COMP360, a synthetic, proprietary formulation of psilocybin. The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at week six. The two trials assessed the effects of two fixed doses—administered three weeks apart—of COMP360 25 mg versus 1 mg. Both demonstrated a highly statistically significant reduction in symptom severity.

Treatment-emergent . . .